Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders

Sánchez-Gomar, Ismael; Sánchez, María Díaz; Sánchez, Antonio José Uclés; Chocán, J L Casado; Suárez-Luna, Nela; Ramírez-Lorca, Reposo; Villadiego, Javier; Toledo‐Aral, Juan José; Echevarría, Miriam

doi:10.3390/ijms17081195

Cited by 10 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that the role of AQP1 in NMOSD remains unknown [ 205 ]. Findings in this study were not replicated by two more studies [ 206 , 207 ]. AQP1 antibody was tested in a group of 249 patients with different types of inflammatory demyelinating diseases, using CBA with Triton X-100.…”

Section: Other Autoantibodies Diseases and Biomarkers Associatedcontrasting

confidence: 99%

“…The AQP1 antibody was undetectable using CBA and detected with low titers by ELISA in few samples. The conclusion was that the study did not allow a sustained detection of anti-AQP1 in serum of NMOSD patients analyzed by CBA or ELISA [ 206 ]. This was further confirmed by the absence of AQP1-antibody using a live CBA in a cohort of patients with NMOSD, MS and controls [ 208 ].…”

Section: Other Autoantibodies Diseases and Biomarkers Associatedmentioning

confidence: 99%

See 1 more Smart Citation

Pattern Recognition of the Multiple Sclerosis Syndrome

2017

View full text Add to dashboard Cite

During recent decades, the autoimmune disease neuromyelitis optica spectrum disorder (NMOSD), once broadly classified under the umbrella of multiple sclerosis (MS), has been extended to include autoimmune inflammatory conditions of the central nervous system (CNS), which are now diagnosable with serum serological tests. These antibody-mediated inflammatory diseases of the CNS share a clinical presentation to MS. A number of practical learning points emerge in this review, which is geared toward the pattern recognition of optic neuritis, transverse myelitis, brainstem/cerebellar and hemispheric tumefactive demyelinating lesion (TDL)-associated MS, aquaporin-4-antibody and myelin oligodendrocyte glycoprotein (MOG)-antibody NMOSD, overlap syndrome, and some yet-to-be-defined/classified demyelinating disease, all unspecifically labeled under MS syndrome. The goal of this review is to increase clinicians’ awareness of the clinical nuances of the autoimmune conditions for MS and NMSOD, and to highlight highly suggestive patterns of clinical, paraclinical or imaging presentations in order to improve differentiation. With overlay in clinical manifestations between MS and NMOSD, magnetic resonance imaging (MRI) of the brain, orbits and spinal cord, serology, and most importantly, high index of suspicion based on pattern recognition, will help lead to the final diagnosis.

show abstract

Section: Other Autoantibodies Diseases and Biomarkers Associatedcontrasting

confidence: 99%

Section: Other Autoantibodies Diseases and Biomarkers Associatedmentioning

confidence: 99%

Pattern Recognition of the Multiple Sclerosis Syndrome

2017

View full text Add to dashboard Cite

show abstract

“…In addition to AQP4, AQP1 is expressed at high levels in human astrocytes, and the AQP1 protein has been detected in NMO‐like lesions in the spinal cord, optic nerves and brain white matter . Although several studies have attempted to detect an AQP1 autoantibody in the serum of patients with NMO and to classify this autoantibody as a new biomarker, some conflicting findings using different detection methods have been reported, causing researchers to question its association with NMOSD .…”

Section: Aqp4‐igg‐seronegative Nmosdmentioning

confidence: 99%

Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder

Chang

2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorderNeuromyelitis optica is an autoimmune inflammatory disorder of the central nervous system that preferentially targets the spinal cord and optic nerve. Following the discovery of circulating antibodies against the astrocytic aquaporin 4 (AQP4) water channel protein, recent studies have expanded our knowledge of the unique complexities of the pathogenesis of neuromyelitis optica and its relationship with the immune response. This review describes and summarizes the recent advances in our understanding of the molecular mechanisms underlying neuromyelitis optica disease pathology and examines their potential as therapeutic targets. Additionally, we update the most recent research by proposing major unanswered questions regarding how peripheral AQP4 antibodies are produced and their entry into the central nervous system, the causes of AQP4-IgG-seronegative disease, why peripheral AQP4-expressing organs are spared from damage, and the impact of this disease on pregnancy.

show abstract

“…In this study we examined the presence of serum IgGs against AQP4, AQP1 and MOG using two cell-based assay (CBA) methods, one previously developed by us [23,24] and the commercial Euroimmun ® Assay widely used abroad for diagnostic purposes. ELISA determinations for the three antibodies were also performed by either commercial, as for AQP4 and MOG, or by in-house developed methods in the case of AQP1-IgG detection.…”

Section: Introductionmentioning

confidence: 99%

Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders

García‐Miranda

Morón-Civanto

Martínez-Olivo

et al. 2019

IJMS

Self Cite

View full text Add to dashboard Cite

The detection of IgG aquaporin-4 antibodies in the serum of patients with Neuromyelitis optica (NMO) has dramatically improved the diagnosis of this disease and its distinction from multiple sclerosis. Recently, a group of patients have been described who have an NMO spectrum disorder (NMOsd) and who are seronegative for AQP4 antibodies but positive for IgG aquaporin-1 (AQP1) or myelin oligodendrocyte glycoprotein (MOG) antibodies. The purpose of this study was to determine whether AQP1 and MOG could be considered new biomarkers of this disease; and if point mutations in the gDNA of AQP4, AQP1 and MOG genes could be associated with the etiology of NMOsd. We evaluated the diagnostic capability of ELISA and cell-based assays (CBA), and analyzed their reliability, specificity, and sensitivity in detecting antibodies against these three proteins. The results showed that both assays can recognize these antigen proteins under appropriate conditions, but only anti-AQP4 antibodies, and not AQP1 or MOG, appears to be a clear biomarker for NMOsd. CBA is the best method for detecting these antibodies; and serum levels of AQP4 antibodies do not correlate with the progression of this disease. So far, the sequencing analysis has not revealed a genetic basis for the etiology of NMOsd, but a more extensive analysis is required before definitive conclusions can be drawn.

show abstract

Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders

Cited by 10 publications

References 30 publications

Pattern Recognition of the Multiple Sclerosis Syndrome

Pattern Recognition of the Multiple Sclerosis Syndrome

Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder

Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders

Contact Info

Product

Resources

About